Tue Nov 24, 2009
UCLA Health System Research and Education: David Geffen School of Medicine at UCLAPatient Care: UCLA Health System
UCLA Urology
Home
For Patients
About Us
Appointments
Innovations and Technology
Newsletters
Webcasts - Urology
News and Events
Maps and Directions
Academic Information
SPORE In Prostate Cancer
How You Can Help
Resources and Publications
Contact Us
Sitemap
Intranet



Request an Appointment

Phone: (310) 794-7700

Visiontree optimal care
patient registration

UCLA Urology #4 in the Nation Highest Ranked in California
UCLA Urology
#4 in the Nation
Highest Ranked in California

Increase (+) Default Decrease (-) Font Size

Services / Kidney Cancer Trials

Trial Information - Kidney Cancer


Kidney Cancer Trials

<< Return to Ongoing Trials

A Phase 3B, Randomized, Open-Label Study of Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-alfa as First-Line Treatment in Subjects with Advanced Renal Cell Carcinoma (IRB# 08-03-080)

A Study of Two Different Combination Therapies for Patients with Advanced Kidney Cancer

Investigator(s): Fairooz Kabbinavar, MD
Accepting Patients: Yes Apply

A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of AV-951 in Combination with Temsirolimus in Subjects with Metastatic Renal Cell Carcinoma (IRB # 07-10-009)

A Study of an Investigational Drug Added to an FDA Approved Drug TORISEL TM Standard of Care Therapy for Subjects with Advanced Kidney Cancer

Investigator(s): Fairooz Kabbinavar, MD
Accepting Patients: Yes Apply

A Randomized Trial of Temsirolimus vs. Sorafenib as Second-Line Therapy in Patients with Advanced Renal Cell Carcinoma Who Have Failed First-Line Sunitinib Therapy (IRB# 07-12-078 )

A study of an Investigational Drug Added to Standard of Care Therapy for Patients with Kidney Cancer

Investigator(s): Fairooz Kabbinavar, MD
Accepting Patients: Yes Apply

A Comparative Study of PET/CT vs. Diagnostic CT for the Detection of Clear Cell Renal Carcinoma in Pre-Surgical Patients with Renal Masses Using Iodine-124 Labeled Chimeric G250 ( 1241-cG250) (IRB# 08-01-059)

Pre-Surgical Detection of Clear Cell Renal Cell Carcinoma Using Radiolabeled G250-Antibody

Investigator(s): Allan Pantuck, MD, MS, FACS
Accepting Patients: Yes Apply
Urology Referral Line: 310-794-7700

A Randomized, Open Label, Multi-Center Phase II Study to Compare Bevacizumab plus RAD001 vs Interferon-alfa2a plus Bevacizumab for the First-Line Treatment of Patients with Metastatic Clear Cell Carcinoma of the Kidney (IRB# 08-06-082)

A Study of Two Combination Therapies for Patients with Advanced Kidney Cancer

Investigator(s): Fairooz Kabbinavar, MD
Accepting Patients: Yes Apply

Sunitinib Treatment of Renal Adjuvant Cancer (S-TRAC): A Randomized Double-Blind Phase 3 Study of Adjuvant Sunitinib vs Placebo in Subjects with High Risk RCC (IRB# 08-06-086 )

A Study of a Post-Surgery Therapy for Patients with Kidney Cancer

Investigator(s): Allan Pantuck, MD, MS, FACS
Accepting Patients: Yes Apply
Urology Referral Line: 310-794-7700

A Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma (VEG 108844) (IRB# 08-09-040)

A Study to Test a New Drug for Treating Kidney Cancer

Investigator(s): Fairooz Kabbinavar, MD
Accepting Patients: Yes Apply

A Treatment Protocol for Patients Continuing from a Prior SU011248 Protocol (IRB# 04-08-087)

A Study of an Investigational Drug for Patients Who Have Participated in Another SUO11248 Study

Investigator(s): Fairooz Kabbinavar, MD
Accepting Patients: Yes Apply

Axitinib (AG-013736) as Second Line Therapy for Metastatic Renal Cell Cancer: AXIS Trial(IRB# 08-05-086)

A Study of an Investigational Therapy Compared with Standard of Care Therapy for Patients with Advanced Kidney Cancer

Investigator(s): Fairooz Kabbinavar, MD
Accepting Patients: Yes Apply

The High-Dose Aldesleukin (IL-2) "SELECT" Trial: A Trial Designed to Prospectively Validate Predictive Models of Response to High Dose IL-2 Treatment in Patients with Metastatic Renal Cell Carcinoma (IRB# 05-12-036)

A Study to Look at Response to High Dose IL-2 Treatment in Patients with Advanced Renal Cell Carcinoma

Investigator(s): Allan Pantuck, MD, MS, FACS
Accepting Patients: Yes Apply
Urology Referral Line: 310-794-7700

Back to top